WFMA - wireless floating microelectrode array for Optic Nerve Diseases

Phase-Based Progress Estimates
Optic Nerve Diseases+5 More
WFMA - wireless floating microelectrode array - Device
All Sexes
What conditions do you have?

Study Summary

This trial will test if it's possible to create artificial vision in people who are blind by implanting electrical stimulator in their brains.

Eligible Conditions
  • Optic Nerve Diseases
  • Eye Injuries
  • Photoreceptor Degeneration
  • Blindness

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: From two-weeks post-op to end of device use, up to 3 years.

Year 3
To test the efficacy of the WFMA-based cortical interface
Year 3
To test the safety of the WFMA-based cortical interface.

Trial Safety

Trial Design

1 Treatment Group

WFMA Cortical Visual Prosthesis Single-arm Study
1 of 1

Experimental Treatment

5 Total Participants · 1 Treatment Group

Primary Treatment: WFMA - wireless floating microelectrode array · No Placebo Group · N/A

WFMA Cortical Visual Prosthesis Single-arm Study
Experimental Group · 1 Intervention: WFMA - wireless floating microelectrode array · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from two-weeks post-op to end of device use, up to 3 years.

Who is running the clinical trial?

University of ChicagoOTHER
917 Previous Clinical Trials
742,342 Total Patients Enrolled
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,250 Previous Clinical Trials
452,348 Total Patients Enrolled
The Chicago LighthouseOTHER
2 Previous Clinical Trials
320 Total Patients Enrolled
Illinois Institute of TechnologyLead Sponsor
19 Previous Clinical Trials
6,739 Total Patients Enrolled
Rush University Medical CenterOTHER
381 Previous Clinical Trials
151,160 Total Patients Enrolled
The University of Texas at DallasOTHER
48 Previous Clinical Trials
105,333 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,055 Previous Clinical Trials
30,975,409 Total Patients Enrolled
1 Trials studying Optic Nerve Diseases
49 Patients Enrolled for Optic Nerve Diseases
Philip R Troyk, PhDPrincipal InvestigatorIllinois Institute of Technology

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing and able to meet the time demands of the study with transportation assistance.
You are willing to be recorded for audio and/or video purposes.
You are motivated by altruism, willing to participate in pioneering science.
You have demonstrated support from a spouse, family or friends.
You have no light perception or bare light perception, in each eye in accordance with relevant ICD-10-CM codes, where the physician has no expectation of improvement through currently approved treatments.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.